Literature DB >> 2012254

Human T-lymphotropic virus type I infection in the Solomon Islands.

R Yanagihara1, A B Ajdukiewicz, R M Garruto, E R Sharlow, X Y Wu, O Alemaena, H Sale, S S Alexander, D C Gajudusek.   

Abstract

To ascertain the prevalence of human T-lymphotropic virus type I (HTLV-I) infection and the occurrence of diseases caused by HTLV-I in the Solomon Islands, we tested 1141 sera from 851 patients (317 females and 534 males), who were hospitalized at the Central Hospital in Honiara between February 1984 and November 1988, for antibodies to HTLV-I using an enzyme-linked immunosorbent assay (ELISA). Sera from 69 of 81 ELISA-positive patients and from 56 ELISA-negative patients were then tested by Western analysis. As verified by strict Western immunoblot criteria, the overall HTLV-I seroprevalence was 2.2% (19/851). Age- and gender-specific prevalence data indicated an age-related acquisition of infection with no sexual predominance. No diagnosis category was over-represented among the seropositive patients. HTLV-I-specific antibodies were found in serum and cerebrospinal fluid samples from one of six patients with spastic paraparesis. As in other Melanesian populations, the majority of ELISA-positive sera could not be confirmed by Western analysis. Reactivity to three or more gag-encoded proteins was found in 85% (45/53) of ELISA-positive, Western blot-indeterminate sera, and 30% (16/53) reacted to p19 and an env gene product but lacked reactivity to p24. Whether or not the high frequency of indeterminate HTLV-I Western immunoblots in the Solomon Islands is indicative of incomplete specific reactivity to HTLV-I or the existence of antigenically related retroviruses is being investigated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012254     DOI: 10.4269/ajtmh.1991.44.122

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Seroepidemiological survey of HTLV-I infection in French Polynesia, Cook Islands and Fiji.

Authors:  E Chungue; J P Boutin; L Le Marchand; G Philippon; A Le Guellec; S Chanteau; J L Cartel; C Gras; P M Martin; J F Roux
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

2.  Highly divergent molecular variants of human T-lymphotropic virus type I from isolated populations in Papua New Guinea and the Solomon Islands.

Authors:  A Gessian; R Yanagihara; G Franchini; R M Garruto; C L Jenkins; A B Ajdukiewicz; R C Gallo; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

3.  Evidence for anti-Plasmodium falciparum antibodies that cross-react with human T-lymphotropic virus type I proteins in a population in Irian Jaya, Indonesia.

Authors:  K R Porter; L Liang; G W Long; M J Bangs; R Anthony; E M Andersen; C G Hayes
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

4.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

5.  Human T-cell leukemia virus type 1 molecular variants, Vanuatu, Melanesia.

Authors:  Olivier Cassar; Corinne Capuano; Laurent Meertens; Eliane Chungue; Antoine Gessain
Journal:  Emerg Infect Dis       Date:  2005-05       Impact factor: 6.883

6.  Human T-cell lymphotropic virus type 1 subtype C molecular variants among indigenous australians: new insights into the molecular epidemiology of HTLV-1 in Australo-Melanesia.

Authors:  Olivier Cassar; Lloyd Einsiedel; Philippe V Afonso; Antoine Gessain
Journal:  PLoS Negl Trop Dis       Date:  2013-09-26

7.  Verification of HTLV-I infection in the Solomon Islands by virus isolation and gene amplification.

Authors:  R Yanagihara; A B Ajdukiewicz; V R Nerurkar; R M Garruto; D C Gajdusek
Journal:  Jpn J Cancer Res       Date:  1991-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.